MARKET

AVDL

AVDL

Avadel Pharmaceu
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.650
-0.030
-0.82%
Opening 11:47 05/24 EDT
OPEN
3.640
PREV CLOSE
3.680
HIGH
3.740
LOW
3.560
VOLUME
87.32K
TURNOVER
196.88K
52 WEEK HIGH
11.59
52 WEEK LOW
3.490
MARKET CAP
215.49M
P/E (TTM)
-2.3701
1D
5D
1M
3M
1Y
5Y
Avadel to Present Clinical Data for FT218 at SLEEP 2022
DUBLIN, Ireland, May 19, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the presentation of clinical data for FT218 in nine posters at th...
GlobeNewswire · 5d ago
Avadel Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will particip...
GlobeNewswire · 6d ago
What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential Approval
Avadel Pharmaceuticals PLC (NASDAQ: AVDL) reported 1Q results and provided updated color on the U.S. marketing application for FT218.
Benzinga · 05/11 19:57
What You Need To Know About Avadel Pharmaceuticals plc's (NASDAQ:AVDL) Investor Composition
The big shareholder groups in Avadel Pharmaceuticals plc ( NASDAQ:AVDL ) have power over the company. Generally...
Simply Wall St. · 05/09 14:05
Recap: Avadel Pharmaceuticals Q1 Earnings
  Avadel Pharmaceuticals (NASDAQ:AVDL) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/09 12:02
BRIEF-Avadel Pharmaceuticals Provides Corporate Update And Reports First Quarter 2022 Financial Results
reuters.com · 05/09 11:25
Avadel Pharmaceuticals Q1 EPS $(0.45) Misses $(0.43) Estimate
Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.43) by 4.65 percent. This is a 95.65 percent decrease over losses of $(0.23) per
Benzinga · 05/09 11:14
Avadel Pharmaceuticals GAAP EPS of -$0.45 misses by $0.02
Avadel Pharmaceuticals press release (NASDAQ:AVDL): Q1 GAAP EPS of -$0.45 misses by $0.02. Cash, cash equivalents and marketable securities were $123.5 million as of March 31, 2022. 
Seekingalpha · 05/09 11:03
More
No Data
Learn about the latest financial forecast of AVDL. Analyze the recent business situations of Avadel Pharmaceu through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AVDL stock price target is 16.30 with a high estimate of 20.00 and a low estimate of 9.00.
High20.00
Average16.30
Low9.00
Current 3.680
EPS
Actual
Estimate
-0.38-0.28-0.19-0.09
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 125
Institutional Holdings: 51.44M
% Owned: 87.13%
Shares Outstanding: 59.04M
TypeInstitutionsShares
Increased
20
1.99M
New
14
1.47M
Decreased
23
741.88K
Sold Out
17
2.06M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.78%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Non-Executive Chairman/Independent Director
Geoffrey Glass
Chief Executive Officer/Chief Operating Officer/Executive Vice President/Director
Gregory Divis
Chief Financial Officer
Thomas McHugh
Other
Richard Kim
Independent Director
Eric Ende
Independent Director
Mark McCamish
Independent Director
Linda Palczuk
Independent Director
Peter Thornton
No Data
No Data
About AVDL
Avadel Pharmaceuticals plc is a biopharmaceutical company. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.

Webull offers kinds of Avadel Pharmaceuticals PLC (ADR) stock information, including NASDAQ:AVDL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVDL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVDL stock methods without spending real money on the virtual paper trading platform.